OCUL — OCULAR THERAPEUTIX INC (Healthcare >> Biotechnology)
OCUL FAQ
What is OCUL's ROE?
OCULAR THERAPEUTIX INC reports a Return on Equity (ROE) of -49.95%.
What is OCUL's dividend yield?
OCULAR THERAPEUTIX INC offers a dividend yield of 0.00%.
What is OCUL's Deepscope Quality Score?
Deepscope rates OCUL's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy OCUL?
Deepscope's AI Timing Score for OCUL is 50 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does OCUL belong to?
OCULAR THERAPEUTIX INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 8.94
Price
0.24
(2.76%)
Day Change
|
|
|---|
OCUL Chất lượng tổng thể của cố phiếu Không tốt ( Chất lượng = 23) và Thời điểm mua ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
Tỷ lệ ROE tương đối thấp
Tỷ lệ ROA tương đối thấp
[-] Tốc độ tăng trưởng ROE dưới mức tiêu chí của chúng tôi.
Lịch sử ROE tương đối thấp
ROE đang giảm đáng kể
ROA quá thấp so với ROE
Tốc độ tăng trưởng ROA dưới mức tiêu chí của chúng tôi.
Tăng trưởng ROA hiện tại đang dưới mức tiêu chí của chúng tôi.
Biên lợi nhuận ròng tương đối thấp.
Lịch sử Biên lợi nhuận ròng tương đối thấp.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Không tốt , Sức khỏe tài chính Không tốt lắm , và khả năng kiếm lợi nhuận Khá , ...
| Yếu tố Chất lượng |
|
39% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 96 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 8.94 |
| PBV / Sector |
3.28 / 4.91
|
| Earning Per Share | -1.36 |
| PE / Sector |
N/A / 18.34
|
| PEG or PE/Growth / Sector |
N/A / 0.61
|
| Average 1M Daily Value |
20.89 M
GREAT
|
| Average 1W Daily Value |
20.39 M
GREAT
|
| Yếu tố Kỹ thuật |
|
57% |
| Sức khỏe tài chính |
|
50% |
| Khả năng kiếm lợi nhuận |
|
60% |
| Lợi tức cho nhà đầu tư |
|
4% |
| Chi tiết đăng ký |
| Analyze Date | 2026-06-13 11:13:36 |
| Symbol | OCUL |
| Name | OCULAR THERAPEUTIX INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 218.96 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1,904.96 / 9,034.83 |
| Tin tức, Dự báo ước tính |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 14 Crosby Drive, Bedford, MA, United States, 01730
Phone: 781 357 4000
Website: https://www.ocutx.com
Employees: 325
Sector: Healthcare >> Biotechnology
Description: Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google